June 7, 2017 / 8:25 PM / 2 months ago

BRIEF-Avexis and Regenxbio announce new exclusive worldwide licenses

1 Min Read

June 7 (Reuters) - Avexis Inc:

* Avexis and Regenxbio announce new exclusive worldwide licenses for the treatment of two rare neurological monogenic disorders using NAV AAV9 vector

* Avexis - ‍Regenxbio to receive upfront payment upon execution, ongoing fees, milestone payments & royalties on net sales of products incorporating NAV AAV9 vector​

* Avexis Inc- intends to move forward with initiating ind-enabling studies in both RTT and ALS, plans to provide details on programs in 2h 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below